Signal from the log
CereVance
20 M$ · Series C · United States · Biotech
Biotech américaine qui développe le solengepras, un inhibiteur de GPR6 contre la maladie de Parkinson, en essai pivot de phase 3 sur 341 participants avec des résultats attendus fin 2026. Le tour, sursouscrit, finance l'entreprise jusqu'à mi-2027 et vient d'investisseurs déjà au capital.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 20 M$
- Stage
- Series C
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
With Double Point Ventures , Gates Frontier , GV , Lightstone Ventures , MQB Partners , SV Health Investors Dementia Discovery Fund , UPMC
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.